Free Trial

Bright Minds Biosciences (DRUG) Stock Price, News & Analysis

-0.03 (-2.31%)
(As of 12:31 PM ET)
Today's Range
50-Day Range
52-Week Range
2,370 shs
Average Volume
25,532 shs
Market Capitalization
$4.88 million
P/E Ratio
Dividend Yield
Price Target
DRUG stock logo

About Bright Minds Biosciences Stock (NASDAQ:DRUG)

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.

DRUG Stock Price History

DRUG Stock News Headlines

Bright Minds Biosciences Inc. (DRUG.CN)
DRUG Bright Minds Biosciences Inc.
Bright Minds Announces Proposed Share Consolidation
See More Headlines
Receive DRUG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bright Minds Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
Book Value
$0.95 per share


Free Float
Market Cap
$5.02 million
Not Optionable
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Mr. Ian McDonald (Age 35)
    Co-Founder, CEO, President & Director
  • Mr. Ryan E. S. K. Cheung B.Com. (Age 46)
    CA, CPA, Chief Financial Officer
    Comp: $87.44k
  • Dr. Jan Torleif Pedersen M.Sc. (Age 59)
    Ph.D., Chief Science Officer & Director
    Comp: $177.46k
  • Dr. Mark A. Smith M.D. (Age 69)
    Ph.D., Chief Medical Officer
    Comp: $238.66k
  • Dr. Emer Leahy M.B.A. (Age 57)
    Ph.D., Consultant

DRUG Stock Analysis - Frequently Asked Questions

How have DRUG shares performed in 2024?

Bright Minds Biosciences' stock was trading at $1.43 on January 1st, 2024. Since then, DRUG shares have decreased by 20.7% and is now trading at $1.1338.
View the best growth stocks for 2024 here

When is Bright Minds Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024.
View our DRUG earnings forecast

When did Bright Minds Biosciences' stock split?

Shares of Bright Minds Biosciences reverse split before market open on Friday, July 14th 2023. The 1-5 reverse split was announced on Friday, July 14th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 14th 2023. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

How do I buy shares of Bright Minds Biosciences?

Shares of DRUG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:DRUG) was last updated on 5/24/2024 by Staff

From Our Partners